Resistant Mycobacterium bovis Bacillus Calmette-Guérin Disease: Implications for Management of Bacillus Calmette-Guérin Disease in Human Immunodeficiency Virus-Infected Children

Simple item page
dc.contributor.authorHesseling A.C.
dc.contributor.authorSchaaf H.S.
dc.contributor.authorVictor T.
dc.contributor.authorBeyers N.
dc.contributor.authorMarais B.J.
dc.contributor.authorCotton M.F.
dc.contributor.authorWiid I.
dc.contributor.authorGie R.P.
dc.contributor.authorVan Helden P.
dc.contributor.authorWarren R.M.
dc.date.accessioned2011-05-15T16:17:38Z
dc.date.available2011-05-15T16:17:38Z
dc.date.issued2004
dc.description.abstractGuidelines for the diagnosis and management of Bacillus Calmette-Guérin (BCG) disease in children are lacking, and there are limited data on drug resistance of Mycobacterium bovis BCG. A 6-month-old HIV-infected infant presented with right axillary adenitis ipsilateral to the site of BCG immunization. M. tuberculosis complex was cultured from axillary lymph nodes and gastric aspirates, and M. bovis BCG was isolated. Susceptibility testing before initiation of therapy demonstrated inherent resistance to isoniazid. The organism acquired rifampin resistance during therapy. This was confirmed by the presence of a mutation in codon 531 (Ser531Tyr) of the rpoB gene. Treatment guidelines for BCG disease with consideration of inherent and possible acquired drug resistance should be established in settings with high rates of vertical HIV transmission and routine BCG vaccination.
dc.description.versionArticle
dc.identifier.citationPediatric Infectious Disease Journal
dc.identifier.citation23
dc.identifier.citation5
dc.identifier.issn08913668
dc.identifier.other10.1097/01.inf.0000126593.21006.ac
dc.identifier.urihttp://hdl.handle.net/10019.1/14303
dc.subjectamikacin
dc.subjectBCG vaccine
dc.subjectciprofloxacin
dc.subjectethambutol
dc.subjectethionamide
dc.subjectisoniazid
dc.subjectofloxacin
dc.subjectpyrazinamide
dc.subjectrifampicin
dc.subjectRNA polymerase beta subunit
dc.subjectantibiotic sensitivity
dc.subjectarticle
dc.subjectaxillary lymph node
dc.subjectBacillus Calmette Guerin disease
dc.subjectbacterium culture
dc.subjectBCG vaccination
dc.subjectcase report
dc.subjectcodon
dc.subjectgene
dc.subjectgene mutation
dc.subjecthuman
dc.subjectHuman immunodeficiency virus
dc.subjecthuman tissue
dc.subjectinfant
dc.subjectinfection
dc.subjectlymph node biopsy
dc.subjectmale
dc.subjectMycobacterium bovis
dc.subjectnonhuman
dc.subjectpractice guideline
dc.subjectpriority journal
dc.subjectrpoB gene
dc.subjectstomach suction
dc.subjectvertical transmission
dc.subjectAnimals
dc.subjectAntitubercular Agents
dc.subjectBCG Vaccine
dc.subjectCattle
dc.subjectDNA-Directed RNA Polymerases
dc.subjectDrug Resistance, Bacterial
dc.subjectHIV Infections
dc.subjectHumans
dc.subjectInfant
dc.subjectIsoniazid
dc.subjectMutation
dc.subjectMycobacterium bovis
dc.subjectRifampin
dc.subjectTuberculosis, Pulmonary
dc.titleResistant Mycobacterium bovis Bacillus Calmette-Guérin Disease: Implications for Management of Bacillus Calmette-Guérin Disease in Human Immunodeficiency Virus-Infected Children
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications